Cargando…
Ex Vivo Chemosensitivity Profiling of Acute Myeloid Leukemia and Its Correlation With Clinical Response and Outcome to Chemotherapy
We evaluated the predictive value of the ex-vivo PharmaFlow PM platform in measuring the pharmacological activity of drug combinations consisting of 20 different chemotherapy regimens (20 Tx) administered in 104 acute myeloid leukemia (AML) patients. The predicted sensitivities of alternative treatm...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767104/ https://www.ncbi.nlm.nih.gov/pubmed/35071002 http://dx.doi.org/10.3389/fonc.2021.793773 |
_version_ | 1784634664036597760 |
---|---|
author | Zhang, Yi Ji, Min Zhao, Jin-Yan Wang, Hua-Feng Wang, Chong-Wu Li, Wei Ye, Jing-Jing Lu, Fei Lin, Li-Hui Gao, Yan-Ting Jin, Jie Li, Li Ji, Chun-Yan Ballesteros, Joan Zhu, Hong-Hu |
author_facet | Zhang, Yi Ji, Min Zhao, Jin-Yan Wang, Hua-Feng Wang, Chong-Wu Li, Wei Ye, Jing-Jing Lu, Fei Lin, Li-Hui Gao, Yan-Ting Jin, Jie Li, Li Ji, Chun-Yan Ballesteros, Joan Zhu, Hong-Hu |
author_sort | Zhang, Yi |
collection | PubMed |
description | We evaluated the predictive value of the ex-vivo PharmaFlow PM platform in measuring the pharmacological activity of drug combinations consisting of 20 different chemotherapy regimens (20 Tx) administered in 104 acute myeloid leukemia (AML) patients. The predicted sensitivities of alternative treatments for each patient were ranked in five 20% categories, from resistant to sensitive (Groups 1–5). The complete remission (CR) rates of the five groups were 0%, 12.5%, 38.5%, 50.0%, and 81.3%, respectively. The heat map showed a good relationship between drug sensitivity with CR (Group 4 + 5 vs. Group 1 + 2+3: 77.5% vs. 27.3%, p = 0.002) and the European Leukemia Net risk group (22.6% vs. 63.6%, p = 0.015). The predicted coincidence rate was 90.9% in Group 1 + 2 and 81.3% in Group 5. According to the recommendations of the PharmaFlow PM platform, the CR rate would have increased by about 16.3% in one cycle. The overall survival (OS) was shorter in patients predicted to be resistant (Group 1 + 2 vs. Group 3 + 4+5, p = 0.086). In multivariable analysis, CR after one cycle was an independent prognostic factor for OS [p = 0.001; 95% CI 0.202 (0.080–0.511)], and ex-vivo chemosensitivity was a potential predictive factor for OS [p = 0.078; 95% CI 0.696 (0.465–1.041)]. To conclude, the PharmaFlow PM platform is a rapid and valuable tool for predicting clinical response and outcomes in AML patients. |
format | Online Article Text |
id | pubmed-8767104 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87671042022-01-20 Ex Vivo Chemosensitivity Profiling of Acute Myeloid Leukemia and Its Correlation With Clinical Response and Outcome to Chemotherapy Zhang, Yi Ji, Min Zhao, Jin-Yan Wang, Hua-Feng Wang, Chong-Wu Li, Wei Ye, Jing-Jing Lu, Fei Lin, Li-Hui Gao, Yan-Ting Jin, Jie Li, Li Ji, Chun-Yan Ballesteros, Joan Zhu, Hong-Hu Front Oncol Oncology We evaluated the predictive value of the ex-vivo PharmaFlow PM platform in measuring the pharmacological activity of drug combinations consisting of 20 different chemotherapy regimens (20 Tx) administered in 104 acute myeloid leukemia (AML) patients. The predicted sensitivities of alternative treatments for each patient were ranked in five 20% categories, from resistant to sensitive (Groups 1–5). The complete remission (CR) rates of the five groups were 0%, 12.5%, 38.5%, 50.0%, and 81.3%, respectively. The heat map showed a good relationship between drug sensitivity with CR (Group 4 + 5 vs. Group 1 + 2+3: 77.5% vs. 27.3%, p = 0.002) and the European Leukemia Net risk group (22.6% vs. 63.6%, p = 0.015). The predicted coincidence rate was 90.9% in Group 1 + 2 and 81.3% in Group 5. According to the recommendations of the PharmaFlow PM platform, the CR rate would have increased by about 16.3% in one cycle. The overall survival (OS) was shorter in patients predicted to be resistant (Group 1 + 2 vs. Group 3 + 4+5, p = 0.086). In multivariable analysis, CR after one cycle was an independent prognostic factor for OS [p = 0.001; 95% CI 0.202 (0.080–0.511)], and ex-vivo chemosensitivity was a potential predictive factor for OS [p = 0.078; 95% CI 0.696 (0.465–1.041)]. To conclude, the PharmaFlow PM platform is a rapid and valuable tool for predicting clinical response and outcomes in AML patients. Frontiers Media S.A. 2022-01-05 /pmc/articles/PMC8767104/ /pubmed/35071002 http://dx.doi.org/10.3389/fonc.2021.793773 Text en Copyright © 2022 Zhang, Ji, Zhao, Wang, Wang, Li, Ye, Lu, Lin, Gao, Jin, Li, Ji, Ballesteros and Zhu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Zhang, Yi Ji, Min Zhao, Jin-Yan Wang, Hua-Feng Wang, Chong-Wu Li, Wei Ye, Jing-Jing Lu, Fei Lin, Li-Hui Gao, Yan-Ting Jin, Jie Li, Li Ji, Chun-Yan Ballesteros, Joan Zhu, Hong-Hu Ex Vivo Chemosensitivity Profiling of Acute Myeloid Leukemia and Its Correlation With Clinical Response and Outcome to Chemotherapy |
title |
Ex Vivo Chemosensitivity Profiling of Acute Myeloid Leukemia and Its Correlation With Clinical Response and Outcome to Chemotherapy |
title_full |
Ex Vivo Chemosensitivity Profiling of Acute Myeloid Leukemia and Its Correlation With Clinical Response and Outcome to Chemotherapy |
title_fullStr |
Ex Vivo Chemosensitivity Profiling of Acute Myeloid Leukemia and Its Correlation With Clinical Response and Outcome to Chemotherapy |
title_full_unstemmed |
Ex Vivo Chemosensitivity Profiling of Acute Myeloid Leukemia and Its Correlation With Clinical Response and Outcome to Chemotherapy |
title_short |
Ex Vivo Chemosensitivity Profiling of Acute Myeloid Leukemia and Its Correlation With Clinical Response and Outcome to Chemotherapy |
title_sort | ex vivo chemosensitivity profiling of acute myeloid leukemia and its correlation with clinical response and outcome to chemotherapy |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767104/ https://www.ncbi.nlm.nih.gov/pubmed/35071002 http://dx.doi.org/10.3389/fonc.2021.793773 |
work_keys_str_mv | AT zhangyi exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy AT jimin exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy AT zhaojinyan exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy AT wanghuafeng exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy AT wangchongwu exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy AT liwei exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy AT yejingjing exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy AT lufei exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy AT linlihui exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy AT gaoyanting exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy AT jinjie exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy AT lili exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy AT jichunyan exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy AT ballesterosjoan exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy AT zhuhonghu exvivochemosensitivityprofilingofacutemyeloidleukemiaanditscorrelationwithclinicalresponseandoutcometochemotherapy |